CoVPN 3501/BLAZE-2: Eli Lilly’s Bamlanivimab (LY-CoV555) Antibody
Read the latest news releases:
- Lilly's neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial, reducing risk by up to 80 percent for residents
- Analysis Demonstrates Effectiveness of LY-CoV555 Antibody in Preventing Symptomatic COVID-19
BLAZE-2 tested monoclonal antibodies. The study enrolled staff and residents in skilled nursing and assisted living facilities with a high risk of exposure to SARS-CoV-2. The study questions were:
- Does the antibody prevent the acquisition of SARS-CoV-2?
- Does the antibody help to prevent the development of more severe COVID-19, or does it reduce the symptoms?
The study was conducted in the United States and enrolled 196 participants.
Monoclonal antibodies are designed to bind to SARS-CoV-2 and prevent the virus from entering healthy cells. Monoclonal antibodies were developed in a lab by the pharmaceutical company Eli Lilly. Monoclonal antibodies cannot give you SARS-CoV-2, nor will they make you sick with COVID-19.
Visit ClinicalTrials.gov - NCT04497987 for additional details about the Eli Lilly monoclonal antibody clinical study to prevent COVID-19.
Together we can help end uncertainty. Join us.
We need your help to keep learning and improving vaccines against COVID-19. We made history with safe and effective vaccines and we’ll keep working as long as there are people to protect, variants emerging, and research answers needed to end this pandemic. To participate:
- Fill out the survey again so we have your most current information to match you with a study, even if you filled it out previously!
- If you haven’t registered to volunteer before, sign up today. There’s still a lot we can do together for those we love.
Content last reviewed on June 12, 2021